Total Payments
$49,052
2024 Payments
$28.49
Companies
28
Transactions
91
Medicare Patients
1,577
Medicare Billing
$166,587
Payment Breakdown by Category
Research$38,099 (77.7%)
Travel$9,471 (19.3%)
Food & Beverage$1,304 (2.7%)
Education$177.98 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38,099 | 20 | 77.7% |
| Travel and Lodging | $9,471 | 5 | 19.3% |
| Food and Beverage | $1,304 | 64 | 2.7% |
| Education | $177.98 | 2 | 0.4% |
Payments by Type
Research
$38,099
20 transactions
General
$10,953
71 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BIOVERATIV THERAPEUTICS INC. | $33,012 | 12 | $0 (2018) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $13,711 | 20 | $0 (2022) |
| PFIZER INC. | $1,293 | 5 | $0 (2023) |
| Janssen Biotech, Inc. | $241.03 | 12 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $106.37 | 2 | $0 (2018) |
| Incyte Corporation | $95.16 | 2 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $65.16 | 4 | $0 (2019) |
| TESARO, Inc. | $54.10 | 3 | $0 (2019) |
| EMD Serono, Inc. | $49.91 | 4 | $0 (2017) |
| Amgen Inc. | $43.84 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28.49 | 2 | Masimo Corporation ($14.31) |
| 2023 | $1,270 | 2 | PFIZER INC. ($1,270) |
| 2022 | $692.00 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($692.00) |
| 2021 | $77.99 | 1 | Incyte Corporation ($77.99) |
| 2019 | $10,026 | 23 | Novartis Pharmaceuticals Corporation ($9,814) |
| 2018 | $35,483 | 41 | BIOVERATIV THERAPEUTICS INC. ($33,012) |
| 2017 | $1,475 | 20 | Novartis Pharmaceuticals Corporation ($1,156) |
All Payment Transactions
91 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/11/2024 | Masimo Corporation | SedLine (Device) | Food and Beverage | Cash or cash equivalent | $14.31 | General |
| Category: Devices | ||||||
| 05/08/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $14.18 | General |
| 11/14/2023 | PFIZER INC. | OXBRYTA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: VOXELOTOR CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 08/01/2023 | PFIZER INC. | OXBRYTA | — | In-kind items and services | $330.00 | Research |
| Study: INCLACUMAB CLINICAL PUBLICATION PROGRAM | ||||||
| 12/12/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | ADAKVEO (Biological) | — | In-kind items and services | $485.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: HEMATOLOGY | ||||||
| 08/02/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | ADAKVEO (Biological) | — | In-kind items and services | $207.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: HEMATOLOGY | ||||||
| 08/11/2021 | Incyte Corporation | — | Education | Cash or cash equivalent | $77.99 | General |
| 11/27/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.46 | General |
| Category: Oncology | ||||||
| 11/26/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Oncology | ||||||
| 11/01/2019 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2019 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: Oncology | ||||||
| 08/26/2019 | Genentech USA, Inc. | GAZYVA (Biological) | Food and Beverage | In-kind items and services | $11.26 | General |
| Category: BioOncology | ||||||
| 07/19/2019 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | Travel and Lodging | In-kind items and services | $297.39 | General |
| Category: HEMATOLOGY | ||||||
| 07/19/2019 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | Travel and Lodging | Cash or cash equivalent | $151.85 | General |
| Category: HEMATOLOGY | ||||||
| 07/19/2019 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | Food and Beverage | In-kind items and services | $134.97 | General |
| Category: HEMATOLOGY | ||||||
| 07/18/2019 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HEMATOLOGY | ||||||
| 07/18/2019 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | Food and Beverage | In-kind items and services | $64.27 | General |
| Category: HEMATOLOGY | ||||||
| 07/01/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: Oncology | ||||||
| 06/25/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2019 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $705.00 | General |
| 06/15/2019 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $269.90 | General |
| 06/13/2019 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $8,047.00 | General |
| 04/25/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $18.87 | General |
| 04/24/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion | BIOVERATIV THERAPEUTICS INC. | $16,506 | 6 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfu | BIOVERATIV THERAPEUTICS INC. | $16,506 | 6 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,125 | 4 |
| VOXELOTOR CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $692.00 | 2 |
| INCLACUMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 338 | 614 | $139,567 | $39,193 |
| 2022 | 11 | 440 | 734 | $154,689 | $44,115 |
| 2021 | 10 | 362 | 636 | $145,621 | $43,015 |
| 2020 | 11 | 437 | 678 | $156,914 | $40,264 |
Total Patients
1,577
Total Services
2,662
Medicare Billing
$166,587
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 77 | 189 | $43,848 | $12,319 | 28.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 54 | 188 | $33,464 | $11,337 | 33.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 72 | 76 | $25,612 | $7,060 | 27.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 58 | 77 | $14,245 | $3,165 | 22.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 21 | 21 | $7,497 | $1,879 | 25.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 18 | $4,608 | $1,572 | 34.1% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 17 | 17 | $4,233 | $1,056 | 24.9% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 12 | 12 | $4,908 | $584.10 | 11.9% |
| 99446 | Telephone, internet, or electronic health record assessment and management with verbal and written report by consulting physician, 5-10 minutes | Facility | 2023 | 16 | 16 | $1,152 | $221.44 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 111 | 222 | $51,504 | $15,029 | 29.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 57 | 132 | $23,496 | $7,135 | 30.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 64 | $16,384 | $4,888 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 65 | 87 | $16,095 | $3,861 | 24.0% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 35 | 35 | $8,715 | $2,767 | 31.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 24 | 25 | $8,425 | $2,577 | 30.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 26 | 26 | $9,282 | $2,479 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 22 | $5,053 | $2,094 | 41.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 17 | $3,067 | $1,058 | 34.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 31 | $2,976 | $935.78 | 31.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 13 | 14 | $5,726 | $781.98 | 13.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 21 | 37 | $2,294 | $281.57 | 12.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 17 | 22 | $1,672 | $227.70 | 13.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 100 | 229 | $53,128 | $16,114 | 30.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 43 | 117 | $20,826 | $6,688 | 32.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 72 | 92 | $17,020 | $4,045 | 23.8% |
About Dr. Darla Liles, MD
Dr. Darla Liles, MD is a Hematology & Oncology healthcare provider based in Greenville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1528051729.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Darla Liles, MD has received a total of $49,052 in payments from pharmaceutical and medical device companies, with $28.49 received in 2024. These payments were reported across 91 transactions from 28 companies. The most common payment nature is "" ($38,099).
As a Medicare-enrolled provider, Liles has provided services to 1,577 Medicare beneficiaries, totaling 2,662 services with total Medicare billing of $166,587. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Greenville, NC
- Active Since 08/24/2005
- Last Updated 02/20/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1528051729
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $33,012
- CRIZANLIZUMAB (Biological) $3,125
- ADAKVEO (Biological) $1,465
- OXBRYTA (Drug) $940.00
- IMBRUVICA (Drug) $228.09
- Imbruvica (Drug) $106.37
- TASIGNA (Drug) $49.78
- ZEJULA (Drug) $42.40
- OPDIVO (Biological) $42.24
- XALKORI (Biological) $38.66
- TREANDA (Drug) $30.23
- KEYTRUDA (Biological) $29.73
- CALQUENCE (Drug) $28.30
- NovoSeven RT (Drug) $28.04
- VORAXAZE (Drug) $27.43
- PROVENGE (Drug) $26.66
- Perjeta (Biological) $25.99
- SUBSYS (Drug) $20.63
- Lonsurf (Drug) $19.05
- Aliqopa (Drug) $17.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Greenville
Dr. Suzanne Fanning, D.o, D.O
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Joe Stephenson, Md, MD
Hematology & Oncology — Payments: $137,970
Hematology & Oncology $137,970
Dr. Paul Walker, M.d, M.D
Hematology & Oncology — Payments: $66,454
Hematology & Oncology $66,454
William Edenfield, Md, MD
Hematology & Oncology — Payments: $31,038
Hematology & Oncology $31,038
Dr. Raid Aljumaily, M.d, M.D
Hematology & Oncology — Payments: $21,498
Hematology & Oncology $21,498
Dr. Jay Walls, Md, MD
Hematology & Oncology — Payments: $13,590
Hematology & Oncology $13,590